Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage?

Clin Infect Dis. 2008 Nov 1;47(9):1226-30. doi: 10.1086/592302.

Abstract

The US Food and Drug Administration has issued a warning that tipranavir may be associated with increased risk of intracranial hemorrhage. We studied 2 large cohorts to estimate the background rate of intracranial hemorrhage and compared it with rates reported among persons who had been exposed to tipranavir.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Age Factors
  • Anti-HIV Agents / adverse effects*
  • California / epidemiology
  • Cohort Studies
  • Databases, Factual
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • Humans
  • Intracranial Hemorrhages / epidemiology
  • Intracranial Hemorrhages / etiology*
  • Male
  • Medicaid / statistics & numerical data
  • Middle Aged
  • Pyridines / adverse effects*
  • Pyrones / adverse effects*
  • Risk Factors
  • Sulfonamides
  • United States / epidemiology
  • Veterans / statistics & numerical data

Substances

  • Anti-HIV Agents
  • Pyridines
  • Pyrones
  • Sulfonamides
  • tipranavir